DWP 700
Alternative Names: DWP-700Latest Information Update: 18 Nov 2022
At a glance
- Originator Daewoong Pharmaceutical
- Class Mesenchymal stem cell therapies; Vascular disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 20 Oct 2022 Preclinical trials in Stroke in South Korea (IV) (Daewoong Pharmaceutical pipeline, October 2022)